Antitrust Claims Survive In Cephalon Pay-To-Delay War
A federal judge has largely preserved antitrust claims in 16 cases lodged against Cephalon Inc. and other drugmakers over allegations that they struck anti-competitive deals in patent suits to keep generic...To view the full article, register now.
Already a subscriber? Click here to view full article